i9h
Britons face paying more for weight-loss jabs... to make them cheaper for Americans
Anti-obesity drug Mounjaro is set rack up sales of nearly £22bn a year by 2030. But Trump's 'America First' policies mean ...
Hosted on MSN17h
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
San Francisco may be seeing a political shift and it could be starting in Chinatown
Huge crowds have come out to Chinatown for Lunar New Year as new political faces take office. She made the look her own with ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
Amber alert issued for missing Virginia Beach boy
Virginia State Police have issued an AMBER alert for a 12-year-old Virginia Beach boy who police say was abducted Friday ...
Why Novo Nordisk surged 14% on new weight-loss drug results
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
interaksyon.philstar4d
Pfizer going ‘all in’ on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer PFE.N is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...
An Ozempic alternative shows promising weight loss results — and Novo Nordisk stock surges 12%
Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Shares Soar as Experimental Shot Shows 22% Weight Loss
Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.